HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2'-O-methyladenosine

RN given refers to parent cpd

Also Known As:

2'-O-methyladenosine, (alpha-D-arabino)-isomer; 2'-O-methyladenosine, (beta-D-arabino)-isomer; adenosine, 2'-O-methyl-

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Adenosine: 12431
        2'-O-methyladenosine: 5
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Purine Nucleosides: 360
    - Adenosine: 12431
      - 2'-O-methyladenosine: 5
  - Ribonucleosides: 49
    - Adenosine: 12431
      - 2'-O-methyladenosine: 5

Experts

1.	Chen, Qianqian: 2 articles (11/2020 - 06/2020)
2.	Ding, Peikun: 2 articles (11/2020 - 06/2020)
3.	Gao, Kaiping: 2 articles (11/2020 - 06/2020)
4.	He, Qihan: 2 articles (11/2020 - 06/2020)
5.	Ling, Lijuan: 2 articles (11/2020 - 06/2020)
6.	Song, Yi: 2 articles (11/2020 - 06/2020)
7.	Wang, Liang: 2 articles (11/2020 - 06/2020)
8.	Wang, Yejun: 2 articles (11/2020 - 06/2020)
9.	Wu, Weiming: 2 articles (11/2020 - 06/2020)
10.	Xiong, Juan: 2 articles (11/2020 - 06/2020)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2020 - "The results showed that a total of 18 types of tRNA modifications and up to seven tRNA-modifying genes were significantly downregulated in NSCLC tumor tissues compared with that in normal tissues, with the 2'-O-methyladenosine (Am) modification displaying the lowest level in tumor tissues. " 11/01/2020 - "FTSJ1 regulates tRNA 2'-O-methyladenosine modification and suppresses the malignancy of NSCLC via inhibiting DRAM1 expression." 06/03/2020 - "Correction: FTSJ1 regulates tRNA 2'-O-methyladenosine modification and suppresses the malignancy of NSCLC via inhibiting DRAM1 expression." 01/01/2021 - "Methylated adenosine (A) modifications such as N 6-methyladenosine (m6A), N 1-methyladenosine (m1A), 2'-O-methyladenosine (Am), N 6,2'-O-dimethyladenosine (m6Am), and N 6,N 6-dimethyladenosine (m6 2A) are typical epigenetic markers of RNA, and they are closely correlated to various diseases including cancer. "
2.	Disease Progression 01/27/2017 - "Based on the fluorescence measurements it was found that the CdTe-thymine conjugate interacted efficiently and selectively not only with adenine, a nucleobase complementary to thymine, but also with adenine-containing modified nucleosides, i.e., 5'-deoxy-5'-(methylthio)adenosine and 2'-O-methyladenosine, the urinary tumor markers which allow monitoring of the disease progression. "
3.	Breast Neoplasms (Breast Cancer) 10/14/2022 - "We found N6-methyladenosine (m6A), 2'-O-methyladenosine (Am), N1-methyladenosine (m1A), N6,2'-O-dimethyladenosine (m6Am), N1-methylguanosine (m1G), 2'-O-methylguanosine (Gm), 5-methylcytidine (m5C) and 2'-O-methylcytidine (Cm) were all decreased in early-stage breast cancer patients, and a nomogram prediction model was constructed. "

Related Drugs and Biologics

1.	Transfer RNA (tRNA)
2.	N-methyladenosine
3.	Tumor Biomarkers (Tumor Markers)
4.	Thymine
5.	RNA (Ribonucleic Acid)
6.	Nucleosides
7.	Adenosine (Adenocard)
8.	Adenine
9.	2'-O-methylcytidine
10.	2'-O-methylguanosine